The prognostic value of p53 mutation in pediatric marrow hypoplasia

被引:7
作者
Abo-Elwafa, Hasnaa A. [1 ]
Attia, Fadia M. [2 ]
Sharaf, Alzahraa E. A. [3 ]
机构
[1] Sohag Univ, Fac Med, Dept Clin Pathol, Sohag, Egypt
[2] Suez Canal Univ, Fac Med, Dept Clin Pathol, Suez Canal, Egypt
[3] Sohag Univ, Fac Med, Dept Pediat, Sohag, Egypt
关键词
BONE-MARROW; APLASTIC-ANEMIA; DNA; OVEREXPRESSION; CANCER; BIOPSIES; FAILURE; PATHWAY;
D O I
10.1186/1746-1596-6-58
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The tumor suppressor gene p53 is involved in the control of cell proliferation, particularly in stressed cells. p 53 gene mutations are the most frequent genetic event found in human cancers. Fanconi Anemia (FA) is the most common representative of inherited bone marrow failure syndromes (IBMFS) with a leukemic propensity. P 53 DNA alteration has not been studied before in Egyptian children with FA. Patients and methods: we investigated p53 mutation in the bone marrow and peripheral blood of forty children, FA (n = 10), acquired aplastic anemia (AAA) (n = 10), and immune thrombocytopenia (ITP) as a control (n = 20), using real-time PCR by TaqMan probe assay Results: Mutation of p53 gene was demonstrated in the BM of 90% (9/10) of children with FA, compared to 10% (1/10) in AAA (p < 0.001), while, no p53 DNA mutation was seen in the control group. A positive correlation between DNA breakage and presence of p53 mutation was seen in FA (p < 0.02, r0.81). Conclusion: mutation of p53 gene in hypoplastic marrow especially FA may represent an early indicator of significant DNA genetic alteration with cancer propensity.
引用
收藏
页数:5
相关论文
共 21 条
[1]   Bone marrow cell cycle markers in inherited bone marrow failure syndromes [J].
Al-Rahawan, Mohamad M. ;
Alter, Blanche P. ;
Bryant, Barbara J. ;
Elghetany, A. Tarek .
LEUKEMIA RESEARCH, 2008, 32 (12) :1793-1799
[2]   Cancer in dyskeratosis congenita [J].
Alter, Blanche P. ;
Giri, Neelam ;
Savage, Sharon A. ;
Rosenberg, Philip S. .
BLOOD, 2009, 113 (26) :6549-6557
[3]   Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients [J].
Anker, P ;
Mulcahy, H ;
Chen, XQ ;
Stroun, M .
CANCER AND METASTASIS REVIEWS, 1999, 18 (01) :65-73
[4]   TP53 TUMOR-SUPPRESSOR GENE AND SKIN CARCINOGENESIS [J].
BASSETSEGUIN, N ;
MOLES, JP ;
MILS, V ;
DEREURE, O ;
GUILHOU, JJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (05) :S102-S106
[5]  
CERVENKA J, 1981, PEDIATRICS, V67, P119
[6]   MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS [J].
CHEN, JD ;
MARECHAL, V ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) :4107-4114
[7]   Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia [J].
Elghetany, MT ;
Vyas, S ;
Yuoh, G .
ANNALS OF HEMATOLOGY, 1998, 77 (06) :261-264
[8]  
Elghetany MT, 2002, ARCH PATHOL LAB MED, V126, P452
[9]   Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 [J].
Fang, SY ;
Jensen, JP ;
Ludwig, RL ;
Vousden, KH ;
Weissman, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :8945-8951
[10]  
FRISCH B, 1974, J CLIN PATHOL, V27, P231, DOI 10.1136/jcp.27.3.231